Cargando…
Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898556/ https://www.ncbi.nlm.nih.gov/pubmed/35249212 http://dx.doi.org/10.1007/s40290-022-00419-x |
_version_ | 1784663681548681216 |
---|---|
author | Fulford-Smith, Antony Leah, Emma Azroyan, Anie De Abadal, Monica Loew, David Hildemann, Steven |
author_facet | Fulford-Smith, Antony Leah, Emma Azroyan, Anie De Abadal, Monica Loew, David Hildemann, Steven |
author_sort | Fulford-Smith, Antony |
collection | PubMed |
description | Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is expected throughout the development and delivery of medicine, healthcare, and information, and potential sources of evidence are legion. To keep pace and go beyond, to innovate, requires efficiencies. Not the disguised cutbacks of political language, but the collaborative constructive efficiencies of shared learning, forming new evidence bases for further progress. Here, we describe the first year of a medical transformation process at a global mid-sized pharmaceutical company. Beginning with a broad review designed to leverage collective intelligence and focus on meaningful outcomes for patients, this process examined and reshaped the structure, culture, and tools of the medical organization and its interactions within and outside the company. We report the findings of the diagnostic phase, outline the solutions implemented to date, and anticipate the next steps in this dynamic evolving journey. |
format | Online Article Text |
id | pubmed-8898556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88985562022-03-07 Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core Fulford-Smith, Antony Leah, Emma Azroyan, Anie De Abadal, Monica Loew, David Hildemann, Steven Pharmaceut Med Current Opinion Pharmaceutical companies with a medical mindset and an empowered Medical Affairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates, so too do expectations. Evidence-based practice, without delay, is expected throughout the development and delivery of medicine, healthcare, and information, and potential sources of evidence are legion. To keep pace and go beyond, to innovate, requires efficiencies. Not the disguised cutbacks of political language, but the collaborative constructive efficiencies of shared learning, forming new evidence bases for further progress. Here, we describe the first year of a medical transformation process at a global mid-sized pharmaceutical company. Beginning with a broad review designed to leverage collective intelligence and focus on meaningful outcomes for patients, this process examined and reshaped the structure, culture, and tools of the medical organization and its interactions within and outside the company. We report the findings of the diagnostic phase, outline the solutions implemented to date, and anticipate the next steps in this dynamic evolving journey. Springer International Publishing 2022-03-06 2022 /pmc/articles/PMC8898556/ /pubmed/35249212 http://dx.doi.org/10.1007/s40290-022-00419-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Current Opinion Fulford-Smith, Antony Leah, Emma Azroyan, Anie De Abadal, Monica Loew, David Hildemann, Steven Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title | Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title_full | Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title_fullStr | Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title_full_unstemmed | Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title_short | Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core |
title_sort | medical affairs transformation in specialty pharma: next-level collaboration at the core |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898556/ https://www.ncbi.nlm.nih.gov/pubmed/35249212 http://dx.doi.org/10.1007/s40290-022-00419-x |
work_keys_str_mv | AT fulfordsmithantony medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore AT leahemma medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore AT azroyananie medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore AT deabadalmonica medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore AT loewdavid medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore AT hildemannsteven medicalaffairstransformationinspecialtypharmanextlevelcollaborationatthecore |